• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Vantive to Invest Over $1B to Transform Kidney Care Over 5 Years

by Fred Pennic 06/02/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Vantive, a vital organ therapy company announced a significant global investment plan of more than US $1B over the next five years. 

– The investment is earmarked for expanding research and development as well as production capacity, aimed at fueling the innovation of digitally-enabled therapies. 

Addressing the Growing Burden of Kidney Disease and Acute Care Needs

The need for innovation in kidney care is urgent. Chronic kidney disease (CKD) is a widespread and costly condition, with annual expenditures in Europe alone estimated to exceed €140B. Factors such as aging populations and rising rates of diabetes and hypertension are driving an increase in the CKD patient population, intensifying pressure on global health systems. CKD is projected to become the fifth leading cause of death globally by 2040. Additionally, there’s a pressing need for acute organ support therapy options, as illustrated by the fact that as many as 60 percent of patients in intensive care units (ICU) may experience acute kidney injury.

Vantive’s investment aims to accelerate the pace of innovation in developing digitally-enabled dialysis and critical care products and services. The goal is to empower earlier and better-informed clinical decision-making, minimize care disruptions, shift kidney care management from reactive to proactive, enhance patient-care team connectivity, and expand access to more consistent, efficient, and personalized care.

“As we prepare to take part in our first ERA Congress as Vantive, we are proud to unveil this significant investment, which underscores our commitment to shaping the future of kidney care and vital organ support,” said Chris Toth, CEO of Vantive. “Better outcomes are possible when care is more accessible, more intuitive, and more connected to the needs of patients as well as the realities of the modern healthcare ecosystem. That’s why we are focused on transforming where and how therapy is delivered – from life-saving critical care for patients in a hospital, to life-sustaining dialysis for patients at home”.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Kidney Disease

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |